Key result
Estrogen and the ER-beta agonist DPN induced dose-dependent increases in cardiac performance (+dP/dt) in rats, with DPN's maximal dose being ~100-fold lower than estrogen's.
Why the study?
Do estrogen and estrogen receptor agonists improve cardiac performance in rats after trauma-hemorrhage?
Do estrogen and estrogen receptor agonists improve cardiac performance in rats after trauma-hemorrhage?
The salutary effects of estrogen on cardiac performance after trauma-hemorrhage are dose-dependent and mediated via the estrogen receptor-beta.
Hypothesis-generating for ER-beta agonists after trauma-hemorrhage; no clinical implications from this rat study.
Although 17beta-estradiol (estrogen) and estrogen receptor (ER) agonist administration after trauma-hemorrhage improves cardiac function, it remains unknown what the optimal estrogen or ER agonist dosage is to elicit this beneficial effect. To study this, the dose-dependent effects of estrogen, propylpyrazole triol (ER-alpha agonist), and diarylpropionitrile (DPN; ER-beta agonist) on heart performance (+dP/dt) were determined in sham rats and in experimental animals at the time of maximal bleedout (MBO) or at 2 h after trauma-hemorrhage. The results showed that estrogen and DPN induced dose-dependent increases in the maximal rate of left ventricular pressure increase (+dP/dt) in all groups, whereas propylpyrazole triol was ineffective at all doses. The maximal dose and the 50% effective dose of DPN were approximately 100-fold lower than those of estrogen. The half-life of estrogen in plasma was approximately 25 min in sham and MBO groups. A positive correlation between the estrogen-induced increase in +dP/dt and survival in MBO rats were observed. These results collectively suggest that the salutary effects of estrogen on cardiac performance are dose-dependent and mediated via ER-beta.
No takes yet. Share an insight, caveat, or question.
Ba et al. (2008) studied trauma-hemorrhage. Estrogen, propylpyrazole triol, and diarylpropionitrile (DPN) vs. Sham rats was evaluated on maximal rate of left ventricular pressure increase (+dP/dt). Estrogen and the ER-beta agonist DPN induced dose-dependent increases in cardiac performance (+dP/dt) in rats, with DPN's maximal dose being ~100-fold lower than estrogen's.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: